NRG delivers 10 patient doses of Lutetium-177 Last week, NRG has delivered lutetium for the first time to an academic hospital and two pharmaceutical parties this month. Sander de Groot, program manager medical isotopes at NRG: “This isotope offers a great perspective for the effective treatment of various cancer indications and with limited side effects.…
SCK CEN and IRE Ready To Start Lutetium-177 Large-Scale Production SCK CEN (ENS Corporate Member) and the National Institute for Radioelements (IRE) are going to start the large-scale production of lutetium-177. This decision opens up opportunities for cancer patients. Lutetium-177 is currently used in hospitals to treat neuroendocrine tumours. Neuroendocrine cells are found primarily in the…
The World’s First Lutetium-177 Produced At Commercial Nuclear Reactor The Canadian nuclear operator Bruce Power announced the world’s first production of lutetium-177 (Lu-177) at a commercial nuclear reactor, its Bruce-7 nuclear power plant in Ontario. This milestone has been achieved thanks to the international cooperation between Bruce Power, Isogen (a Kinectrics and Framatome company), and…
NRG|PALLAS and Curium Expand Cooperation in Lu-177 Production NRGIPALLAS (ENS Corporate Member) and Curium have signed a long-term agreement to expand the current cooperation to include the production of lutetium-177 (Lu-177). This agreement will enable Curium to supply about 70,000 doses of Lu-177 annually, which will help about 14,000 patients per year. Curium and NRG…
Framatome Advances Towards Producing Lu-177 In Romania Framatome (ENS Corporate Member) and Nuclearelectrica have announced the successful outcome of the feasibility study which assessed the possibility of producing medical isotope Lutetium-177 (Lu-177) at the Cernavoda nuclear power plant in Romania. The two companies have now launched the implementation of the project, covering detailed engineering, procurement,…
Framatome To Study Medical Radioisotopes Production At Argentinian NPPs Framatome (ENS Corporate Member) and Nucleoeléctrica Argentina have signed an agreement to conduct a pre-feasibility study on installing systems for producing short-lived radioisotopes, such as Lutetium-177, at the nuclear power plants operated by the Argentine company: Atucha I, Atucha II, and Embalse. The study is expected…